OptimizeRx publishes corporate presentation on its Dynamic Audience Activation Platform and FY2026 guidance of USD 109-114 million revenue

Reuters03-18
OptimizeRx publishes corporate presentation on its Dynamic <a href="https://laohu8.com/S/1AZ.SI">Audience</a> Activation Platform and FY2026 guidance of USD 109-114 million revenue

OptimizeRx released a corporate presentation outlining its Dynamic Audience Activation Platform (DAAP) and its use in predictive, privacy-focused marketing across healthcare professional and patient channels. The presentation said DAAP deals typically range between about USD 0.5 million and USD 1.5 million. OptimizeRx reported a stock price of USD 5.93 and a market capitalization of about USD 111.3 million. The presentation listed cash and cash equivalents of USD 23.4 million and total debt of USD 25.7 million. OptimizeRx also reported net revenue retention of 116% and revenue per average full-time employee of USD 839,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment